Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175044 | 0.93 | KDM4E (0.32) | ALDH1A1MAPTTDP1L3MBTL1ALOX5 | |
| SCHEMBL20199172 | 0.92 | KDM4E (0.31) | ALDH1A1MAPTTDP1L3MBTL1ALOX5 | |
| SCHEMBL20199179 | 0.90 | ALOX5 (0.32) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL18457533 | 0.89 | ALDH1A1 (0.41) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL24647969 | 0.89 | ALDH1A1 (0.41) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL20199122 | 0.87 | PDK2 (0.33) | ALOX5 | |
| SCHEMBL20174805 | 0.87 | PDK2 (0.33) | ALOX5 | |
| SCHEMBL20174850 | 0.87 | PDK2 (0.31) | ALDH1A1MAPTGPR3POLBTDP1 | |
| SCHEMBL20174841 | 0.87 | PDK2 (0.31) | ALDH1A1MAPTGPR3POLBTDP1 | |
| SCHEMBL20175064 | 0.87 | KDM4E (0.31) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781366-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-09-22 | — | — | US | disclosed |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781366-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | ALDH1A1 33/4885MAPT 811/4885HPGD 2229/4885 |
| US-20180148639-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | ALDH1A1 33/4885MAPT 811/4885HPGD 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.